3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Keratosis, Actinic
5
Uterine Cervical Neoplasms
3
Uterine Cervical Dysplasia
2
Papillomavirus Infections
2
Melanoma
2
Hemangioma, Capillary
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)
1
Virus Diseases
1
Vaginal Neoplasms
1
Urinary Bladder Neoplasms
1
Skin Neoplasms
1
Sexually Transmitted Diseases
1
Precancerous Conditions
1
Pigmentation Disorders
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hemangioma
1
HPV
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Condylomata Acuminata
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Basal Cell
1
Carcinoma in Situ
1
Interventions
Paclitaxel
34
Carboplatin
27
pembrolizumab
20
Bevacizumab
16
Letrozole
13
Megestrol Acetate
10
Cisplatin
9
lenvatinib
8
olaparib
7
dostarlimab
7
Metformin
7
durvalumab
6
abemaciclib
6
Radiotherapy
6
Everolimus
6
niraparib
5
Specimen Handling
5
Nivolumab
5
Medroxyprogesterone Acetate
5
Magnetic Resonance Spectroscopy
5
Gemcitabine
5
Fluorouracil
5
Docetaxel
5
Biopsy
5
temsirolimus
4
rucaparib
4
Oxaliplatin
4
Fulvestrant
4
Doxorubicin
4
sapanisertib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Endometrial Neoplasms
×
Imiquimod
×
Clear all
NCT06686043
2024-11-13
HPV-VIM
Baylor College of Medicine
Phase 2
Recruiting
85 enrolled